Micrus Endovascular Corp

Micrus Endovascular — Merger or Acquisition (July 2010)

16 slides from Micrus Endovascular's merger presentation, Jul 12, 2010

  1. Slide 1: Introduction to Codman: A Global Medical Device Company

    INTRODUCTION TO CODMAN: A Global Medical Device Company Leading the Evolution in Neuroscience July, 2010

  2. Slide 2: Our Mission

    Our Mission: To Improve the quality of life in many more patients worldwide by developing innovative solutions across a broad spectrum of neurological conditions

  3. Slide 3: J&J's Global Presence

    $23.6B $15.8B $22.5B J&J’s Global Presence • One of the World’s Largest Health Care Companies • 115,000 Employees • 250 Operating Companies In 57 Countries • Selling Products in Over 175 Countries Diversified Business Medical Devices & Diagnostics 38% Consumer 26% Pharmaceutical 36%

  4. Slide 4: Our Credo responsibilities

    “We believe our first responsibility is to doctors, nurses and patients…” “We are also responsible to the communities we serve…” “Our final responsibility is to our stockholders…” “We are also responsible to our employees…”

  5. Slide 5: The DePuy Companies of Johnson & Johnson

    Sports Medicine and Minimally Invasive Joint Therapies Joint Reconstruction and Trauma Neurological and Neurovascular Treatment The DePuy Companies of Johnson & Johnson

  6. Slide 6: Add Images of R&D, product, physician

    6 Add Images of R&D, product, physician with company, physician with patient

  7. Slide 7: Codman global footprint and facilities

    7 • Products sold in over 50 countries • Global workforce of over 500 people • Worldwide headquarters: • Raynham, MA • Manufacturing locations: • Massachusetts • Germany • Switzerland • Mexico

  8. Slide 8: Codman & Shurtleff is Creating a Global Presence in Neuroscience

    Codman & Shurtleff, Inc. is Creating a Global Presence in Neuroscience • A Total Neuroscience Company with a broad product line • From a Foundation with Neurosurgeons worldwide • Integrated Cordis neurovascular (CNV) business into Codman in 2009 • Launched MEDSTREAM neuromodulation drug pump in 2009

  9. Slide 9: Vast Unmet Need Remains in Treating Neurological Disorders

    Each year, there are over 30 million newly diagnosed patients worldwide with neurological disease Vast Unmet Need Remains in Treating Neurological Disorders Ø Worldwide, 1-in-5, or 1.7billion people, suffer from neurological diseases, yet less than 1-in-5 of these people are treated § In the US, Str

  10. Slide 10: We Offer an Industry-leading Product Portfolio

    We Offer an Industry-leading Product Portfolio Major Conditions / Diseases Products • Acquired hydrocephalus (via. tumor, surgery, absorption) • Normal Pressure Hydro (NPH) Hydrocephalus Treat Valves: Fixed and CHPV® BACTISEAL® Catheter • Post-craniotomy care • Traumatic Brain Injury (TBI) • (post)

  11. Slide 11: We are investing in Transformational Technologies

    We are investing in Transformational Technologies* Neuromodulation Stroke Therapeutics & Diagnostics Neurosurgery & NeuroCritical Care Neurostimulators SNS Selective nerve stimulation for under-treated diseases, including epilepsy, depression, stroke Drug Delivery Build on MEDSTREAM pump with new co

  12. Slide 12: Competitive Advantages

    Competitive Advantages ENTERPRISE Stent Platform Global Footprint & Alignment World-class Prof Ed Capabilities Codman: Total Neurosciences Approach

  13. Slide 13: DePuy Institute, LLC

    DePuy Institute, LLC State-of-the-art 70,000 sq ft facility • Hydrocephalus • Neurovascular • Neuro Critical Care • Raising Awareness • NPH Patient Campaign • NPH Referral Development • Professional Education • Hydro Symposia • Embolic Training Courses • New DePuy Institute Addressing the unmet educ

  14. Slide 14: Our Commitment

    Our Commitment Strengthen Global Presence in Neuroscience Offer an Industry-leading Product Portfolio Advance Breakthrough Future Therapies

  15. Slide 15: Forward Looking Statements

    Forward Looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties mat

  16. Slide 16: Additional information about the proposed transaction

    In connection with the proposed transaction, Micrus Endovascular Corporation intends to file a definitive proxy statement and other relevant materials with the Securities and Exchange Commission (the “SEC”). Before making any voting decision with respect to the proposed transaction, stockholders of

Micrus Endovascular — Merger or Acquisition (July 2010) on 6ix